• Mashup Score: 0

    Targeting the cardiovascular (CV)-kidney-metabolic (CKM) axis may improve outcomes in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD) by addressing interconnected metabolic, kidney, and CV risks.

    Tweet Tweets with this article
    • Turn the latest research into real-world results. In this CME activity, we provide a practical roadmap for applying new treatments for patients with heart and kidney conditions. Build your confidence and improve patient care today ▢️ https://t.co/xMYYHKPGAO #CME https://t.co/3sru4qPXzi

  • Mashup Score: 1
    Home - 3 day(s) ago

    Activity Overview

    Tweet Tweets with this article
    • πŸ«€ Elevate your HCM management with insights on cardiac myosin inhibitors. πŸ“Š Compare current and emerging treatmentsβ€”evaluating efficacy, safety, and suitabilityβ€”to strengthen your evidence-based strategies. Deepen your expertise: πŸ‘‰ https://t.co/fbk5LkxjMy https://t.co/3jdwOPKVba

  • Mashup Score: 0
    Home - 8 day(s) ago

    Friday, September 26, 2025 8:00 pm – 9:30 pm CT Minneapolis Hilton Hotel | Minneapolis, Minnesota Grand Ballroom D CME/CNE/CPE Hybrid Hypertrophic cardiomyopathy (HCM) is the most common inherited heart disease in the United States. If left untreated, it is associated with significant morbidity and mortality. Use of conventional pharmacologic therapy has been met with challenges. As a result, cardiac myosin inhibition has emerged as a novel strategy, which targets the underlying pathological hypercontracti

    Tweet Tweets with this article
    • πŸ”₯ Big gaps in HF care? Not anymore. ✨ Discover how nsMRAs are changing the game for HFpEF & HFmrEF. πŸ“Š Dive into the latest data & see where they fit in your treatment plan. πŸ‘‰ https://t.co/AReJOeDWt6 https://t.co/fkDgUHILqQ

  • Mashup Score: 0

    A dedicated curriculum to educate clinicians on the risks associated with severely elevated triglycerides and the potential role of novel treatments to optimize outcomes in patients with sHTG and FCS.

    Tweet Tweets with this article
    • FCS patients have lifelong severe HTG (>1000 mg/dL), while multifactorial HTG is episodic and influenced by 2Β° factors. The dyslipidemic, hepatic, and pancreatic complications of FCS are serious, requiring frequent hospitalizations. Learn the latest! πŸ“Œ https://t.co/CX8l5TfeEu https://t.co/UXi4JfTrex

  • Mashup Score: 1
    Home - 9 day(s) ago

    Friday, September 26, 2025 8:00 pm – 9:30 pm CT Minneapolis Hilton Hotel | Minneapolis, Minnesota Grand Ballroom D CME/CNE/CPE Hybrid Hypertrophic cardiomyopathy (HCM) is the most common inherited heart disease in the United States. If left untreated, it is associated with significant morbidity and mortality. Use of conventional pharmacologic therapy has been met with challenges. As a result, cardiac myosin inhibition has emerged as a novel strategy, which targets the underlying pathological hypercontracti

    Tweet Tweets with this article
    • πŸ«€ Stay ahead in HCM care! Explore emerging therapies, compare treatment approaches, and gain confidence in using cardiac myosin inhibitors for your patients. πŸ‘‰ https://t.co/EpH9sme7sa https://t.co/ZZ6jddwora